CA2185228A1 - Concentre de fibrinogene non traite cryoprecipite - Google Patents
Concentre de fibrinogene non traite cryoprecipiteInfo
- Publication number
- CA2185228A1 CA2185228A1 CA 2185228 CA2185228A CA2185228A1 CA 2185228 A1 CA2185228 A1 CA 2185228A1 CA 2185228 CA2185228 CA 2185228 CA 2185228 A CA2185228 A CA 2185228A CA 2185228 A1 CA2185228 A1 CA 2185228A1
- Authority
- CA
- Canada
- Prior art keywords
- plasma
- concentrate
- fibrinogen
- bonding
- viscosity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000535 fibrinogen concentrate Substances 0.000 title claims abstract description 23
- 239000007787 solid Substances 0.000 claims abstract description 82
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 76
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 76
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 76
- 239000012141 concentrate Substances 0.000 claims description 59
- 102000009027 Albumins Human genes 0.000 claims description 24
- 108010088751 Albumins Proteins 0.000 claims description 24
- 229960004072 thrombin Drugs 0.000 claims description 19
- 108090000190 Thrombin Proteins 0.000 claims description 18
- 241000283690 Bos taurus Species 0.000 claims description 14
- 230000035876 healing Effects 0.000 claims description 13
- 102000003886 Glycoproteins Human genes 0.000 claims description 11
- 108090000288 Glycoproteins Proteins 0.000 claims description 11
- 238000001727 in vivo Methods 0.000 claims description 11
- 102000001621 Mucoproteins Human genes 0.000 claims description 8
- 108010093825 Mucoproteins Proteins 0.000 claims description 8
- 239000000227 bioadhesive Substances 0.000 claims description 8
- 239000003106 tissue adhesive Substances 0.000 claims description 8
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 4
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 241000283073 Equus caballus Species 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 239000000504 antifibrinolytic agent Substances 0.000 claims description 3
- 230000010261 cell growth Effects 0.000 claims description 3
- 239000000701 coagulant Substances 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 108010071289 Factor XIII Proteins 0.000 claims description 2
- 102000016359 Fibronectins Human genes 0.000 claims description 2
- 108010067306 Fibronectins Proteins 0.000 claims description 2
- 108010094028 Prothrombin Proteins 0.000 claims description 2
- 102100027378 Prothrombin Human genes 0.000 claims description 2
- 229940012444 factor xiii Drugs 0.000 claims description 2
- 229940039716 prothrombin Drugs 0.000 claims description 2
- 230000001567 anti-fibrinolytic effect Effects 0.000 claims 2
- 229940082620 antifibrinolytics Drugs 0.000 claims 2
- 239000004034 viscosity adjusting agent Substances 0.000 claims 2
- 102000013566 Plasminogen Human genes 0.000 claims 1
- 108010051456 Plasminogen Proteins 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 description 87
- 239000000047 product Substances 0.000 description 70
- 238000012360 testing method Methods 0.000 description 63
- 235000018102 proteins Nutrition 0.000 description 54
- 102000004169 proteins and genes Human genes 0.000 description 54
- 108090000623 proteins and genes Proteins 0.000 description 54
- 238000000034 method Methods 0.000 description 50
- 238000010257 thawing Methods 0.000 description 50
- 210000001519 tissue Anatomy 0.000 description 43
- 241001481789 Rupicapra Species 0.000 description 39
- 230000008569 process Effects 0.000 description 35
- 238000012797 qualification Methods 0.000 description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 102000004506 Blood Proteins Human genes 0.000 description 18
- 108010017384 Blood Proteins Proteins 0.000 description 18
- 239000000853 adhesive Substances 0.000 description 18
- 230000001070 adhesive effect Effects 0.000 description 18
- 238000005119 centrifugation Methods 0.000 description 16
- 238000003556 assay Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 238000012545 processing Methods 0.000 description 12
- 230000007704 transition Effects 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000009102 absorption Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 238000004026 adhesive bonding Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 230000003595 spectral effect Effects 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 7
- 238000004064 recycling Methods 0.000 description 7
- 229910001868 water Inorganic materials 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000007710 freezing Methods 0.000 description 6
- 230000008014 freezing Effects 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 230000002035 prolonged effect Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 108010073385 Fibrin Proteins 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000565 sealant Substances 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 208000031737 Tissue Adhesions Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003872 anastomosis Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000020764 fibrinolysis Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000007775 late Effects 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000012134 supernatant fraction Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000000153 supplemental effect Effects 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000009388 chemical precipitation Methods 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000004023 fresh frozen plasma Substances 0.000 description 2
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 239000000990 laser dye Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005375 photometry Methods 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- -1 rl~-~innqon Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001501610 Atule Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- JFPVXVDWJQMJEE-QMTHXVAHSA-N Cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)C(=NOC)C1=CC=CO1 JFPVXVDWJQMJEE-QMTHXVAHSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101150039033 Eci2 gene Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 210000000540 fraction c Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001046 green dye Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940106780 human fibrinogen Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000010327 methods by industry Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000019624 protein content Nutrition 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Concentré de fibrinogène cryoprécipité de plasma non traité de mammifères comprenant de 6 à environ 44 % de produits solides dont une proportion de 5 à 98 % est constituée par du fibrinogène coagulable, ledit cryoprécipité présentant une viscosité comprise entre 80 et 430 centipoises et une force de rupture à la traction comprise entre 1 et 8 lb-f/pouce de largeur.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22081594A | 1994-03-31 | 1994-03-31 | |
| US08/220,815 | 1994-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2185228A1 true CA2185228A1 (fr) | 1995-10-12 |
Family
ID=22825094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2185228 Abandoned CA2185228A1 (fr) | 1994-03-31 | 1995-03-31 | Concentre de fibrinogene non traite cryoprecipite |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0758903A4 (fr) |
| CA (1) | CA2185228A1 (fr) |
| DE (1) | DE758903T1 (fr) |
| WO (1) | WO1995026749A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112915281B (zh) * | 2021-03-12 | 2022-12-16 | 臻叶生物科技有限公司 | 一种无抗凝剂的prp生物膜制备装置及方法 |
| IL310285A (en) | 2021-08-13 | 2024-03-01 | Biotest Ag | Fibrinogen preparations and preparation methods |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2492458A (en) * | 1944-12-08 | 1949-12-27 | Jr Edgar A Bering | Fibrin foam |
| AT359652B (de) * | 1979-02-15 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines gewebekleb- stoffes |
| DE3203775A1 (de) * | 1982-02-04 | 1983-08-11 | Behringwerke Ag, 3550 Marburg | Fibrinogenzubereitung, verfahen zu ihrer herstellungund ihre verwendung |
| DE3230849A1 (de) * | 1982-08-19 | 1984-02-23 | Behringwerke Ag, 3550 Marburg | Pasteurisiertes human-fibrinogen (hf) und verfahren zu dessen herstellung |
-
1995
- 1995-03-31 WO PCT/US1995/003987 patent/WO1995026749A1/fr not_active Ceased
- 1995-03-31 CA CA 2185228 patent/CA2185228A1/fr not_active Abandoned
- 1995-03-31 EP EP95914220A patent/EP0758903A4/fr not_active Withdrawn
- 1995-03-31 DE DE0758903T patent/DE758903T1/de active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1995026749A1 (fr) | 1995-10-12 |
| EP0758903A1 (fr) | 1997-02-26 |
| DE758903T1 (de) | 1997-07-10 |
| EP0758903A4 (fr) | 1998-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5420250A (en) | Phase transfer process for producing native plasma protein concentrates | |
| Sierra et al. | A method to determine shear adhesive strength of fibrin sealants | |
| US5330974A (en) | Therapeutic fibrinogen compositions | |
| TW404836B (en) | Biological adhesive composition | |
| EP2099505B1 (fr) | Biogel | |
| US4407787A (en) | Collagenous dressing | |
| FI77985B (fi) | Foerfarande foer framstaellning av en fibrinogenprodukt. | |
| JP2511462B2 (ja) | 一成分組織接着剤およびその製造方法 | |
| DE69329875T2 (de) | Verfahren zur herstellung eines mit plättchenfaktoren angereicherten biologischen klebstoffes und seine verwendung | |
| AU2004201982B2 (en) | A Method for Producing a Preparation Based on Fibrinogen and Fibronectin as Well as Protein Compositions Obtainable According to This Method | |
| FR2510408A1 (fr) | Colle pour tissus | |
| JPH0260339B2 (fr) | ||
| DK151611B (da) | Fremgangsmaade til fremstilling af et vaevsklaebestof paa basis af humane eller animalske proteiner fra blod | |
| JPH05286999A (ja) | 安定なフィブリノーゲン溶液 | |
| SE453799C (sv) | Vävnadsbindemedel innefattande fibrinogen och faktor XIII samt förfarande för dess framställning | |
| JPH11502537A (ja) | 合成架橋を用いる組織接着剤 | |
| KR20090122279A (ko) | 고체상 피브리노겐 제제 | |
| CA2185228A1 (fr) | Concentre de fibrinogene non traite cryoprecipite | |
| US6916911B1 (en) | Use of fibrinogen multimers | |
| EP1202754B1 (fr) | Utilisation de multimeres de fibrinogene | |
| EP1057490A2 (fr) | Utilisation de l'acide tranexemique dans la préparation d'une composition de fibrinogène humain | |
| JP4771594B2 (ja) | フィブリノーゲンおよびフィブロネクチンをベースとする製剤を生成するための方法ならびにこの方法により入手可能なタンパク質組成物 | |
| US5644032A (en) | Process for producing fibrinogen concentrates | |
| JPH0928695A (ja) | 凝固促進剤入採血管 | |
| Wang | Fibrin glue with improved adhesive strength |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |